{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:00:00Z","timestamp":1793973600072,"version":"4.8.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Most patients with locally advanced hepatocellular carcinoma (HCC) recur within the liver following systemic therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine whether stereotactic body radiation therapy (SBRT) improves outcomes in patients with locally advanced HCC compared with sorafenib alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This multicenter phase 3 randomized clinical trial randomized patients with HCC 1:1 to sorafenib or SBRT followed by sorafenib, stratified by performance status, liver function, degree of metastases, and macrovascular invasion. Eligible patients had HCC unsuitable for or refractory to standard local-regional therapies and were candidates for first-line systemic therapy. Data were collected from April 2013 to March 2021, and data were analyzed from July 2022 to August 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Personalized SBRT, 27.5 to 50 Gy in 5 fractions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end point was overall survival (OS). Secondary end points were progression-free survival (PFS), adverse events, and quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 193 patients randomized, 177 were eligible. Accrual was stopped early due to a change in standard-of-care systemic therapy. Of 177 included patients, 150 (84.7%) were male, and the median (IQR) age was 66 (60-72) years. Macrovascular invasion was seen in 131 (74.0%). As of July 1, 2022, the median OS was 12.3 months (90% CI, 10.6-14.3) with sorafenib vs 15.8 months (90% CI, 11.4-19.2) following SBRT and sorafenib (hazard ratio [HR], 0.77; 90% CI, 0.59-1.01; 1-sided <jats:italic>P<\/jats:italic>\u2009=\u2009.06). Adjusting for stratification factors, OS was improved with SBRT (HR, 0.72; 95% CI, 0.52-0.99; 2-sided <jats:italic>P<\/jats:italic>\u2009=\u2009.04). Median PFS was improved from 5.5 months (95% CI, 3.4-6.3) with sorafenib to 9.2 months (95% CI, 7.5-11.9) with SBRT and sorafenib (HR, 0.55; 95% CI, 0.40-0.75; 2-sided <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). Treatment-related grade 3 or higher adverse events were seen in 37 of 88 (42%) and 39 of 83 (47%) of patients treated with sorafenib vs SBRT and sorafenib, respectively (<jats:italic>P<\/jats:italic>\u2009=\u2009.52). There were 2 treatment-related deaths in the sorafenib group (death not otherwise specified and liver failure) and 1 in the SBRT and sorafenib group (lung infection). At 6 months, improved quality of life was seen in 2 of 20 (10%) and 6 of 17 (35%) of patients treated with sorafenib and SBRT and sorafenib, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this phase 3 randomized clinical trial, among patients with locally advanced HCC, SBRT was associated with a clinically important but not statistically significant improved overall survival compared with sorafenib alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT01730937\">NCT01730937<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.5403","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T16:02:08Z","timestamp":1734624128000},"page":"136","source":"Crossref","is-referenced-by-count":115,"title":["Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma"],"prefix":"10.1001","volume":"11","author":[{"given":"Laura A.","family":"Dawson","sequence":"first","affiliation":[{"name":"University Health Network\u2013Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Winter","sequence":"additional","affiliation":[{"name":"NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania"},{"name":"American College of Radiology, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[{"name":"University Health Network\u2013Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew X.","family":"Zhu","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Krishnan","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Guha","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Kachnic","sequence":"additional","affiliation":[{"name":"NYP\/Columbia University Medical Center\/Herbert Irving Comprehensive Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Gillin","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Craig","sequence":"additional","affiliation":[{"name":"University Health Network\u2013Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence M.","family":"Williams","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hosni","sequence":"additional","affiliation":[{"name":"University Health Network\u2013Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chen","sequence":"additional","affiliation":[{"name":"University Health Network\u2013Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Noonan","sequence":"additional","affiliation":[{"name":"Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene J.","family":"Koay","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Sinha","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"Lock","sequence":"additional","affiliation":[{"name":"London Regional Cancer Program, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Ohri","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Dorth","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guila","family":"Delouya","sequence":"additional","affiliation":[{"name":"CHUM-Centre Hospitalier de l\u2019Universite de Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Swaminath","sequence":"additional","affiliation":[{"name":"Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Moughan","sequence":"additional","affiliation":[{"name":"NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania"},{"name":"American College of Radiology, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Crane","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"coi240070r1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040.","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"coi240070r2","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"coi240070r3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ctrv.2010.07.006","article-title":"Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.","volume":"37","author":"Raoul","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"coi240070r4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"coi240070r5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/hepr.13438","article-title":"Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan.","volume":"50","author":"Kudo","year":"2020","journal-title":"Hepatol Res"},{"issue":"3","key":"coi240070r6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jhep.2020.09.026","article-title":"Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial.","volume":"74","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"coi240070r7","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.ijrobp.2004.01.032","article-title":"Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis.","volume":"59","author":"Kato","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi240070r8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ijrobp.2023.03.064","article-title":"Transarterial chemoembolization with drug-eluting beads vs. stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter randomized phase II trial (the TRENDY trial).","volume":"117","author":"M\u00e9ndez Romero","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"coi240070r9","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma.","volume":"31","author":"Bujold","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi240070r10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial.","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"coi240070r11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.radonc.2020.11.033","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion.","volume":"156","author":"Munoz-Schuffenegger","year":"2021","journal-title":"Radiother Oncol"},{"issue":"4","key":"coi240070r12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"coi240070r13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi240070r14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ijrobp.2022.09.060","article-title":"Lenvatinib synergistically promotes radiation therapy in hepatocellular carcinoma by inhibiting Src\/STAT3\/NF-?B-mediated epithelial-mesenchymal transition and metastasis.","volume":"115","author":"Weng","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"coi240070r15","doi-asserted-by":"publisher","first-page":"9443","DOI":"10.1158\/0008-5472.CAN-07-1473","article-title":"Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation.","volume":"67","author":"Plastaras","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"coi240070r16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ijrobp.2015.11.048","article-title":"Phase 1 trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma.","volume":"94","author":"Brade","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"coi240070r17","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s10238-022-00972-4","article-title":"External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"23","author":"Li","year":"2023","journal-title":"Clin Exp Med"},{"issue":"2","key":"coi240070r18","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases.","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"coi240070r19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"7-8","key":"coi240070r20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0021-9681(74)90015-0","article-title":"The randomization and stratification of patients to clinical trials.","volume":"27","author":"Zelen","year":"1974","journal-title":"J Chronic Dis"},{"issue":"3","key":"coi240070r21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.prro.2022.11.013","article-title":"Insights from image guided radiation therapy credentialing for the NRG Oncology RTOG 1112 Liver Stereotactic Body Radiation Therapy Trial.","volume":"13","author":"Craig","year":"2023","journal-title":"Pract Radiat Oncol"},{"issue":"9","key":"coi240070r22","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1200\/JCO.2002.07.093","article-title":"Measuring health-related quality of life in patients with hepatobiliary cancers: the Functional Assessment of Cancer Therapy-Hepatobiliary Questionnaire.","volume":"20","author":"Heffernan","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi240070r23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/annonc\/mdj072","article-title":"Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma.","volume":"17","author":"Steel","year":"2006","journal-title":"Ann Oncol"},{"issue":"4","key":"coi240070r24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"coi240070r25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.radonc.2019.08.009","article-title":"Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: necessity to subclassify Barcelona Clinic Liver Cancer stage C.","volume":"141","author":"Kim","year":"2019","journal-title":"Radiother Oncol"},{"issue":"24","key":"coi240070r26","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.18.02184","article-title":"Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study.","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"issue":"19","key":"coi240070r27","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma.","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi240070r28","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi240070r29","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1186\/s12885-016-2868-y","article-title":"Single administration of selective internal radiation therapy versus continuous treatment with sorafenib in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.","volume":"16","author":"Gandhi","year":"2016","journal-title":"BMC Cancer"},{"issue":"8","key":"coi240070r30","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"8","key":"coi240070r31","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.3390\/cancers14081901","article-title":"Outcomes and toxicities of modern combined modality therapy with atezolizumab plus bevacizumab and radiation therapy for hepatocellular carcinoma.","volume":"14","author":"Manzar","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2827892\/jamaoncology_dawson_2024_oi_240070_1744234490.82794.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T15:01:15Z","timestamp":1744297275000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2827892"}},"subtitle":["The NRG Oncology\/RTOG 1112 Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.5403","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}